Matches in SemOpenAlex for { <https://semopenalex.org/work/W1496148027> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W1496148027 endingPage "3258" @default.
- W1496148027 startingPage "3258" @default.
- W1496148027 abstract "AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA3258 TKI258 (formerly CHIR-258) is an oral, multi-targeted RTK inhibitor of FGFR, VEGFR, PDGFRβ, FLT3 and c-KIT. Given that FGFR 1-4 and their FGF ligands are implicated in the pathogenesis of melanoma, we investigated TKI258 efficacy in melanoma models, based on it’s potential activity against both tumor cells via inhibition of FGFR, and against the tumor vasculature by targeting FGFR, VEGFR and PDGFRβ. In vitro activity of TKI258 was tested in clonogenic assays against a panel of melanoma cell lines and limited passage human melanoma cells propagated in mice. All melanoma cell lines were characterized for expression of FGFR1-4 and mutational status of B-Raf or Ras. In the in vitro clonogenic assays on soft agar, TKI258 activity was observed in all melanoma cells regardless of FGFR1-4 expression levels, or wild-type/mutant Ras/B-Raf status. In vivo efficacy was evaluated in two different subcutaneous melanoma xenograft models: CHL-1 (WT K-Ras and WT B-Raf) and A375M (mutant B-Raf) in athymic nude mice. These xenograft models have similar patterns of expression of FGFR1-4, but differ in Ras/Raf pathway status. Daily oral administration of TKI258 at doses that inhibit FGFR signaling in vivo resulted in significant tumor growth inhibition of both CHL-1 and A375M tumor xenograft models. Antitumor activity of TKI258 was also evaluated in vivo in combination with the chemotherapeutic agents carboplatin and paclitaxel, which are used clinically to treat melanoma. Compared to monotherapy, the combination of TKI258 with carboplatin plus paclitaxel resulted in enhanced activity against both CHL-1 and A375M tumors and was well tolerated. In the CHL-1 model, treatment with carboplatin plus paclitaxel at maximum tolerated doses showed no tumor growth inhibition (TGI), whereas TKI258 therapy demonstrated approximately 44% TGI. The combination of all three agents exhibited 70% TGI. In the A375 model, animals dosed with the carboplatin + paclitaxel combination resulted in 35% TGI, TKI258 treatment alone showed 58% TGI and the combination of all three agents resulted in 73% TGI. In conclusion, anti-tumor activity of TKI258 in these models is likely due to multiple mechanisms, including inhibition of FGFR 1-4 and/or additional TKI258 targets expressed by these melanoma cell lines, and it’s anti-angiogenic activity via inhibition of VEGFR and PDGFRβ. These results demonstrate that TKI258 is effective as a single agent and in combination with chemotherapy in preclinical melanoma models, thus providing a basis for TKI258 clinical trials in melanoma.*equal contributing authors" @default.
- W1496148027 created "2016-06-24" @default.
- W1496148027 creator A5007005277 @default.
- W1496148027 creator A5007764738 @default.
- W1496148027 creator A5013699933 @default.
- W1496148027 creator A5015280909 @default.
- W1496148027 creator A5020814446 @default.
- W1496148027 creator A5029409714 @default.
- W1496148027 creator A5031779697 @default.
- W1496148027 creator A5033062662 @default.
- W1496148027 creator A5042175121 @default.
- W1496148027 creator A5045035432 @default.
- W1496148027 creator A5052768746 @default.
- W1496148027 creator A5062815708 @default.
- W1496148027 creator A5076370404 @default.
- W1496148027 creator A5081175984 @default.
- W1496148027 creator A5091240262 @default.
- W1496148027 date "2007-05-01" @default.
- W1496148027 modified "2023-09-26" @default.
- W1496148027 title "TKI258 is an effective multi-targeted receptor tyrosine kinase (RTK) inhibitor against xenograft models of human melanoma." @default.
- W1496148027 hasPublicationYear "2007" @default.
- W1496148027 type Work @default.
- W1496148027 sameAs 1496148027 @default.
- W1496148027 citedByCount "0" @default.
- W1496148027 crossrefType "journal-article" @default.
- W1496148027 hasAuthorship W1496148027A5007005277 @default.
- W1496148027 hasAuthorship W1496148027A5007764738 @default.
- W1496148027 hasAuthorship W1496148027A5013699933 @default.
- W1496148027 hasAuthorship W1496148027A5015280909 @default.
- W1496148027 hasAuthorship W1496148027A5020814446 @default.
- W1496148027 hasAuthorship W1496148027A5029409714 @default.
- W1496148027 hasAuthorship W1496148027A5031779697 @default.
- W1496148027 hasAuthorship W1496148027A5033062662 @default.
- W1496148027 hasAuthorship W1496148027A5042175121 @default.
- W1496148027 hasAuthorship W1496148027A5045035432 @default.
- W1496148027 hasAuthorship W1496148027A5052768746 @default.
- W1496148027 hasAuthorship W1496148027A5062815708 @default.
- W1496148027 hasAuthorship W1496148027A5076370404 @default.
- W1496148027 hasAuthorship W1496148027A5081175984 @default.
- W1496148027 hasAuthorship W1496148027A5091240262 @default.
- W1496148027 hasConcept C101544691 @default.
- W1496148027 hasConcept C117262875 @default.
- W1496148027 hasConcept C121608353 @default.
- W1496148027 hasConcept C126322002 @default.
- W1496148027 hasConcept C150903083 @default.
- W1496148027 hasConcept C170493617 @default.
- W1496148027 hasConcept C207001950 @default.
- W1496148027 hasConcept C2777658100 @default.
- W1496148027 hasConcept C2781230642 @default.
- W1496148027 hasConcept C502942594 @default.
- W1496148027 hasConcept C71924100 @default.
- W1496148027 hasConcept C74373430 @default.
- W1496148027 hasConcept C82867764 @default.
- W1496148027 hasConcept C86803240 @default.
- W1496148027 hasConcept C98274493 @default.
- W1496148027 hasConceptScore W1496148027C101544691 @default.
- W1496148027 hasConceptScore W1496148027C117262875 @default.
- W1496148027 hasConceptScore W1496148027C121608353 @default.
- W1496148027 hasConceptScore W1496148027C126322002 @default.
- W1496148027 hasConceptScore W1496148027C150903083 @default.
- W1496148027 hasConceptScore W1496148027C170493617 @default.
- W1496148027 hasConceptScore W1496148027C207001950 @default.
- W1496148027 hasConceptScore W1496148027C2777658100 @default.
- W1496148027 hasConceptScore W1496148027C2781230642 @default.
- W1496148027 hasConceptScore W1496148027C502942594 @default.
- W1496148027 hasConceptScore W1496148027C71924100 @default.
- W1496148027 hasConceptScore W1496148027C74373430 @default.
- W1496148027 hasConceptScore W1496148027C82867764 @default.
- W1496148027 hasConceptScore W1496148027C86803240 @default.
- W1496148027 hasConceptScore W1496148027C98274493 @default.
- W1496148027 hasLocation W14961480271 @default.
- W1496148027 hasOpenAccess W1496148027 @default.
- W1496148027 hasPrimaryLocation W14961480271 @default.
- W1496148027 hasRelatedWork W1593299612 @default.
- W1496148027 hasRelatedWork W1965188536 @default.
- W1496148027 hasRelatedWork W1981911530 @default.
- W1496148027 hasRelatedWork W1987321907 @default.
- W1496148027 hasRelatedWork W2006920740 @default.
- W1496148027 hasRelatedWork W2064022140 @default.
- W1496148027 hasRelatedWork W2081747183 @default.
- W1496148027 hasRelatedWork W2088482691 @default.
- W1496148027 hasRelatedWork W2171406886 @default.
- W1496148027 hasRelatedWork W2328467277 @default.
- W1496148027 hasRelatedWork W2331053472 @default.
- W1496148027 hasRelatedWork W2368230640 @default.
- W1496148027 hasRelatedWork W2728483795 @default.
- W1496148027 hasRelatedWork W2805631082 @default.
- W1496148027 hasRelatedWork W2886527726 @default.
- W1496148027 hasRelatedWork W2888438759 @default.
- W1496148027 hasRelatedWork W2955126505 @default.
- W1496148027 hasRelatedWork W2956072323 @default.
- W1496148027 hasRelatedWork W2956152423 @default.
- W1496148027 hasRelatedWork W3177664578 @default.
- W1496148027 hasVolume "67" @default.
- W1496148027 isParatext "false" @default.
- W1496148027 isRetracted "false" @default.
- W1496148027 magId "1496148027" @default.
- W1496148027 workType "article" @default.